Malignant tumors are currently the second leading cause of death. Immuno-oncology uses the body's immune system to identify and kill tumor cells. Stemirna is committed to applying mRNA technology for the field of immuno-oncology. We use mRNA technology to activate specific antigen T cells and improve the tumor immune microenvironment, thus bringing revolutionary technology to tumor immunotherapy research.
Compared with traditional vaccines, mRNA vaccines have great advantages in efficacy, speed of development, scalability and safety during production. Multiple viral antigens can be integrated into a single mRNA, enabling the production of complex multi-antigen vaccines that are difficult to achieve with traditional techniques. In addition, the way mRNA vaccines work mimics the process of virus infection, further enhancing the immune response of B cells and T cells.